Clinical trial · Observational
Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma
Non-interventional Study to Evaluate Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma
NCT03211377CI-TRIAL-00028553unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-interventional study to observe the safety and efficiency of chemotherapy for potentially resectable locally advanced esophagogastric junction
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagogastric Junction Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- neoadjuvant therapy group
- description
- Preoperation chemotherapy treatment for patients up to four cycles
- label
- adjuvant therapy
- description
- Postoperation chemotherapy treatment for patients up to six cycles
- label
- Perioperative therapy
- description
- Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
Primary outcomes (1)
- measure
- disease free survival(DFS)
- timeFrame
- up to 3 years
- description
- time from surgery to disease recurrence or death
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytological proved locally advanced esophagogastric junction cancer * ECOG performance status ≦2 * Stage IIa-IIIc * No distant metastasis (M0) * Sign in Informed Consent Form Exclusion Criteria: * History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product * Pregnancy or lactation women, * Inadequate hematopoietic function： WBC≦3,500/mm3; ANC≦1,500/mm3; Platelet≦80,000/mm3 * Inadequate organ function which is defined as below: Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN); serum creatinine \> 1.5 mg/dL, and Ccr \> 60 ml/min (estimated by Cockcroft-Gault formulation); * Symptomatic peripheral neuropathy * Receiving a concomitant treatment with other fluoropyrimidines * Fluoropyrimidines (DPD) congenital absence
References
Publications (0)
Data not yet available
No reference posted for this study.